Search Results

Targeted alpha therapy with bismuth-213 and actinium-225: Meeting future demand.

• Authors : Bruchertseifer F; European Commission, Joint Research Centre (JRC), Karlsruhe, Germany.; Kellerbauer A

Subjects: Actinium/Actinium/Actinium/*therapeutic use ; Alpha Particles/Alpha Particles/Alpha Particles/*therapeutic use ; Bismuth/Bismuth/Bismuth/*therapeutic use

• Source: Journal of labelled compounds & radiopharmaceuticals [J Labelled Comp Radiopharm] 2019 Sep; Vol. 62 (11), pp. 794-802. Date of Electronic Publication: 2019 Aug 01.Publisher: Wiley Country of Publication: England NLM ID: 7610510 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1099-1344

Record details

Innovation, Impact, and Strategic Importance of Alpha-Emitting Radionuclides.

• Authors : Mirzadeh S; Nuclear and Radiochemistry Group, Isotope and Fuel Cycling Technology Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee, USA. Electronic address: .

Subjects: Alpha Particles/Alpha Particles/Alpha Particles/*therapeutic use ; Neoplasms/Neoplasms/Neoplasms/*radiotherapy ; Radioisotopes/Radioisotopes/Radioisotopes/*therapeutic use

• Source: Journal of medical imaging and radiation sciences [J Med Imaging Radiat Sci] 2019 Dec; Vol. 50 (4 Suppl 1), pp. S21-S25. Date of Electronic Publication: 2019 Aug 13.Publisher: Elsevier Country of Publication: United States NLM ID: 101469694 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

High-Specific-Activity- 131 I-MIBG versus 177 Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma.

• Authors : Jha A; Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, Maryland.; Taïeb D

Subjects: 3-Iodobenzylguanidine/3-Iodobenzylguanidine/3-Iodobenzylguanidine/*therapeutic use ; Adrenal Gland Neoplasms/Adrenal Gland Neoplasms/Adrenal Gland Neoplasms/*radiotherapy ; Adrenal Gland Neoplasms/Adrenal Gland Neoplasms/Adrenal Gland Neoplasms/*secondary

• Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Jun 01; Vol. 27 (11), pp. 2989-2995. Date of Electronic Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate cancer.

• Authors : Vlachostergios PJ; Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, USA.; Niaz MJ

Subjects: Antigens, Surface/Antigens, Surface/Antigens, Surface/*analysis ; Glutamate Carboxypeptidase II/Glutamate Carboxypeptidase II/Glutamate Carboxypeptidase II/*analysis ; Lutetium/Lutetium/Lutetium/*therapeutic use

• Source: The Prostate [Prostate] 2021 Apr; Vol. 81 (5), pp. 279-285. Date of Electronic Publication: 2021 Jan 19.Publisher: Wiley-Liss Country of Publication: United States NLM ID: 8101368 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Education Full Text (H.W. Wilson)

Record details

Radiolabeling of Biogenic Magnetic Nanoparticles with Rhenium-188 as a Novel Agent for Targeted Radiotherapy.

• Authors : Akbari-Karadeh S; Department of Medical Radiation Engineering, Shahid Beheshti University, Tehran, Iran.; Aghamiri SMR

Subjects: Magnetics* ; Nanoparticles*; Alphaproteobacteria/Alphaproteobacteria/Alphaproteobacteria/*metabolism

• Source: Applied biochemistry and biotechnology [Appl Biochem Biotechnol] 2020 Feb; Vol. 190 (2), pp. 540-550. Date of Electronic Publication: 2019 Aug 08.Publisher: Humana Press Country of Publication: United States NLM ID: 8208561 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Frontiers in radionuclide imaging and therapy, a chemical journey from naturally radioactive elements to targeted theranostic agents.

• Authors : Casini A; School of Chemistry, Cardiff University, CF10 3AT, Cardiff, UK.; Orvig C

Subjects: Radioisotopes* ; Radionuclide Imaging* ; Radiotherapy*

• Source: Dalton transactions (Cambridge, England : 2003) [Dalton Trans] 2017 Oct 31; Vol. 46 (42), pp. 14433-14434.Publisher: Royal Society of Chemistry Country of Publication: England NLM ID: 101176026 Publication Model: Print Cited Medium: Internet ISSN:

Record details

177 Lu-PSMA Radioligand Therapy for Prostate Cancer.

• Authors : Fendler WP; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California .; Department of Nuclear Medicine, Ludwig Maximilians University of Munich, Munich, Germany.

Subjects: Radioisotopes*; Antigens, Surface/Antigens, Surface/Antigens, Surface/*metabolism ; Glutamate Carboxypeptidase II/Glutamate Carboxypeptidase II/Glutamate Carboxypeptidase II/*metabolism

• Source: Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2017 Aug; Vol. 58 (8), pp. 1196-1200. Date of Electronic Publication: 2017 Jun 29.Publisher: Society of Nuclear Medicine Country of Publication: United States NLM ID: 0217410 Publication Model: Print-Electronic Cited Medium: Internet

Record details

[ 177 Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent.

• Authors : Schottelius M; Chair for Pharmaceutical Radiochemistry, Technische Universität München, Walther-Meissner-Strasse 3, 85748 Garching, Germany.; Osl T

Subjects: Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*pharmacokinetics ; Lutetium/Lutetium/Lutetium/*pharmacokinetics ; Lymphoma/Lymphoma/Lymphoma/*drug therapy

• Source: Theranostics [Theranostics] 2017 Jun 11; Vol. 7 (9), pp. 2350-2362. Date of Electronic Publication: 2017 Jun 11 (Print Publication: 2017).Publisher: Ivyspring International Publisher Country of Publication: Australia NLM ID: 101552395 Publication Model: eCollection Cited Medium: Internet

Record details

Polymethylmethacrylate and radioisotopes in vertebral augmentation: an explanation of underlying principles.

• Authors : Hirsch AE; Massachusetts General Hospital, Boston, MA, USA. ; Rosenstein BS

Subjects: Fractures, Compression/Fractures, Compression/Fractures, Compression/*radiotherapy ; Polymethyl Methacrylate/Polymethyl Methacrylate/Polymethyl Methacrylate/*therapeutic use ; Radioisotopes/Radioisotopes/Radioisotopes/*administration & dosage

• Source: Pain physician [Pain Physician] 2009 Sep-Oct; Vol. 12 (5), pp. 887-91.Publisher: American Society of Interventional Pain Physicians Country of Publication: United States NLM ID: 100954394 Publication Model: Print Cited Medium:

Record details